Show simple item record

dc.contributor.advisorOdhav, Bharti
dc.contributor.advisorChikwamba, Rachel
dc.contributor.authorMoodley, Nadine
dc.date.accessioned2009-11-06T11:39:44Z
dc.date.available2011-03-31T22:20:06Z
dc.date.issued2009
dc.identifier.other325129
dc.identifier.urihttp://hdl.handle.net/10321/486
dc.descriptionSubmitted in fulfillment of the requirements for the Degree of Master of Technology: Biotechnology, Department of Biotechnology and Food Technology, Faculty of Applied Sciences, Durban University of Technology, South Africa,2009.en_US
dc.description.abstractNearly half of all individuals living with HIV worldwide at present are woman and the best current strategy to prevent sexually transmitted HIV is antiretrovirals (ARVs). Microbicides are ARV’s which directly target viral entry and avert infection at mucosal surfaces. However, most promising ARV entry inhibitors are biologicals which are costly to manufacture and deliver to resource-poor areas. Microbicides formulated as simple gels, which are currently not commonly used in ARV therapy, show immense potential for use in prevention and treatment of multidrug-resistant viral infections in developing countries. Among the most potent HIV entry inhibitory molecules are lectins, which target the high mannose N-linked glycans which are displayed on the surface of HIV envelope glycoproteins. Of the microbicides, the red algal protein griffithsin (GRFT) has potent anti-HIV inhibitory activity and is active by targeting the terminal mannose residues on high mannose oligosaccharides. It has a total of 6 carbohydrate binding sites per homodimer, which likely accounts for its unparalleled potency. The antiviral potency of GRFT, coupled with its lack of cellular toxicity and exceptional environmental stability make it an ideal active ingredient of a topical HIV microbicide. v Scytovirin (SVN) is an equally potent anti-HIV protein, isolated from aqueous extracts of the cyanbacterium, Scytonema varium. Low, nanomolar concentrations of SVN have been reported to inactivate laboratory strains and primary isolates of HIV- 1. The inhibition of HIV by SVN involves interactions between the protein and HIV-1 envelope glycoproteins gp120, gp160 and gp41. Current recombinant production methods for GRFT and SVN molecules are unfortunately hampered by inadequate production capacities. This project therefore aimed to determine if these molecules can be produced in plant cell culture systems. The transgenic tobacco cell culture system was evaluated to determine if it can be an alternative, cost effective production system for these molecules. Results of the study show that the microbicide genes can be cloned into plant transformation vectors, used to successfully transform SR1 tobacco cell lines and adequately produce 3.38ng and 10.5ng of GRFT and SVN protein respectively, per gram of SR1 tobacco callus fresh weight. The promising results attained in this study form the basis for further work in optimising plant cell based production systems for producing valuable anti-HIV microbicides, a possible means to curbing the elevated HIV infection rates worldwide.en_US
dc.description.sponsorshipCSIRen_US
dc.format.extent147 pen_US
dc.language.isoenen_US
dc.subjectBiotechnologyen_US
dc.subjectTobacco--Cytologyen_US
dc.subjectHIV infections--Preventionen_US
dc.subjectPlant cell cultureen_US
dc.subjectCell linesen_US
dc.titleExpression of anti-HIV peptides in tobacco cell culture systemsen_US
dc.typeThesisen_US
dc.dut-rims.pubnumDUT-000370


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record